8-K: Milestone Scientific Faces NYSE Delisting Threat

Milestone Scientific Inc. received a notice from NYSE American regarding non-compliance with continued listing standards, requiring a compliance plan by November 7, 2025.

Summary

• Milestone Scientific Inc. received a letter from NYSE American LLC on October 8, 2025, stating non-compliance with continued listing standards.
• The specific sections of non-compliance are 1003(a)(ii) and (iii) of the NYSE American Company Guide.
• The company must submit a plan of compliance to NYSE American by November 7, 2025.
• If the plan is accepted, the company may continue its listing, subject to periodic reviews.
• Failure to submit an accepted plan, or to regain compliance by April 8, 2027, or to make progress consistent with the plan, will result in delisting procedures.
• Management is actively pursuing options to address the deficiency and intends to submit a compliance plan before the deadline.

Sentiment

Score: 2

Explanation: The company received a formal notice of non-compliance with NYSE American listing standards, indicating a significant operational or financial issue that could lead to delisting, posing a substantial threat to its market presence and investor confidence.

Negatives

• Received a formal notice of non-compliance with NYSE American continued listing standards.
• Faces potential delisting from NYSE American if compliance is not regained.
• The company must dedicate resources to developing and executing a compliance plan under a tight deadline.

Risks

• Potential delisting from NYSE American, which could significantly impact stock liquidity and investor confidence.
• Failure of the compliance plan to be accepted by NYSE American.
• Inability to regain compliance with listing standards by the April 8, 2027 deadline.
• Negative perception among investors and potential impact on the company's ability to raise capital in the future.

Future Outlook

Management intends to pursue options to address the deficiency and submit a compliance plan to NYSE American by the November 7, 2025 deadline, aiming to regain compliance and maintain its listing.

Management Comments

• Management is pursuing options to address the deficiency and intends to submit a compliance plan on or before the deadline set by the Exchange.

Industry Context

Receiving a delisting notice is a serious event for any publicly traded company, often signaling underlying operational, financial, or governance issues. While specific industry trends are not detailed in this filing, such notices typically lead to increased scrutiny from investors and can affect a company's market valuation and access to capital.

Stakeholder Impact

• Shareholders face potential loss of liquidity and value if the company is delisted from NYSE American.
• Employees may experience uncertainty regarding the company's future and market standing.
• The company's reputation and ability to attract future investment may be negatively impacted.

Next Steps

• Submit a plan of compliance to NYSE American by November 7, 2025.
• Regain compliance with NYSE American listing standards by April 8, 2027, if the plan is accepted.

Key Dates

Recommendation

The company faces a significant risk of delisting from NYSE American due to non-compliance with listing standards. While management intends to submit a compliance plan, the uncertainty surrounding its acceptance and the ability to regain compliance by April 8, 2027, poses a substantial threat to shareholder value, liquidity, and investor confidence. This situation warrants a cautious approach, and a sell recommendation reflects the high downside risk and potential for significant share price depreciation.

Keywords

Milestone Scientific, NYSE American, delisting, listing standards, compliance, 8-K, SEC filing, corporate governance, regulatory notice